stella
Breast CancerNovember 2022Summary reviewed April 2026

Keytruda Plus Chemotherapy Cut Death Risk 27% in Triple-Negative Breast Cancer

Adding Keytruda (pembrolizumab) to chemotherapy reduced the risk of death by 27% in patients with triple-negative breast cancer — one of the hardest subtypes to treat and a population with historically limited options.

What the trial was testing

The KEYNOTE-355 enrolled 847 patients with breast cancer. The study was sponsored by Merck and tracked outcomes across the full group of patients who matched the trial's eligibility profile.

It was a large trial designed to confirm whether the treatment works well enough for wider use. Trials at this stage are designed to produce evidence regulators and physicians can act on — not just observations to follow up later.

What the results showed

27% reduction in risk of death when Keytruda was added to chemotherapy for TNBC.

New England Journal of Medicine · 2022 · NCT03036488

These findings — that in risk of death for triple-negative breast cancer patients treated with Keytruda plus chemotherapy — were published in the New England Journal of Medicine and represent the headline result of the study.

Researchers tracked outcomes across 847 patients enrolled in the trial. The result was consistent enough across the group that the team felt confident reporting it.

What this means for patients

For patients with breast cancer, this result changes the calculus on what to ask their care team about. Whether it changes day-to-day care depends on factors like disease subtype, prior treatments, and where the patient is in their care journey.

What you can do now

Keytruda plus chemotherapy is now FDA-approved for PD-L1-positive triple-negative breast cancer. If you have TNBC, ask your oncologist about PD-L1 testing — eligibility for this regimen depends on your PD-L1 score.

Eligibility for the treatments mentioned above depends on specific test results and clinical history. Bring this summary, the trial name, and your most recent labs or pathology report to your next visit.

Open breast cancer trials

RecruitingObservational study

CAPIVASERTIB REGULATORY POSTMARKETING SURVEILLANCE IN KOREA

To fulfil the post-approval commitment of MFDS to conduct post-marketing surveillance, this study is designed to assess the known safety profile, identify previously unsuspected adverse reactions and to evaluate the effectiveness of Capivasertib under conditions of routine daily medical practice in Korea.

Busan, South Korea +16 more
RecruitingSafety & dosing

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

This trial will look at a drug called sigvotatug vedotin (SGN-B6A) alone and with pembrolizumab, with or without chemotherapy, to find out whether it is safe for people who have solid tumors. It will study sigvotatug vedotin to find out what its side effects are. A side effect is anything the drug does besides treating cancer. It will also study whether sigvotatug vedotin works to treat solid tumors. The study will have four parts. * Part A of the study will find out how much sigvotatug vedotin should be given to participants. * Part B will use the dose found in Part A to find out how safe sigvotatug vedotin is and if it works to treat solid tumors. * Part C of the study will find out how safe sigvotatug vedotin is in combination with these other drugs. * Part D will include people who have not received treatment. This part of the study will find out how safe sigvotatug vedotin is in combination with these other drugs and if these combinations work to treat solid tumors. * In Parts C and D, participants will receive sigvotatug vedotin with either: * Pembrolizumab or, * Pembrolizumab and carboplatin, or * Pembrolizumab and cisplatin.

Anchorage, Alaska, United States +24 more